A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects

Vaccine

Volumn 24, Issue 7, 2006, Pages 914-920

  De Bruyn, Guy ^a,b,p   Vargas Cortez, Mauricio ^c,q   Warren, Terri ^d   Tyring, Stephen K ^e   Fife, Kenneth H ^f   Lalezari, Jacob ^g   Brady, Rebecca C ^h   Shahmanesh, Mohsen ⁱ   Kinghorn, George ^j   Beutner, Karl R ^k   Patel, Rajul ^l   Drehobl, Margaret A ^m   Horner, Patrick ⁿ   Kurtz, Terrance O ^o   McDermott, Sharon ^c   Wald, Anna ^b   Corey, Lawrence ^a,b,i  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Westover Heights Clinic   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f INDIANA UNIVERSITY   (United States)

^g Quest Clinical Research   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ Whittal Street Clinic ^*  (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^l ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^m SCRIPPS CLINIC   (United States)

ⁿ ST MARY S HOSPITAL   (United Kingdom)

^o LM Leonard Research Institute   (United States)

^p ZA   (United States)

^q ELI LILLY AND COMPANY   (United States)

more..

Author keywords

Genital herpes; Herpes simplex virus; Randomized controlled trial; Therapeutic vaccine

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN H; HERPES SIMPLEX VACCINE; PLACEBO; UNCLASSIFIED DRUG; VALACICLOVIR; VIRUS DNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENE DELETION; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOCOMPETENCE; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS SHEDDING;

ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 31844455180     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.088     Document Type: Article

References (19)

1. S.E. Straus, L. Corey, R.L. Burke, B. Savarese, G. Barnum, and P.R. Krause Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes Lancet 343 8911 1994 1460 1463
2. S.E. Straus, A. Wald, R.G. Kost, R. McKenzie, A.G. Langenberg, and P. Hohman Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial J Infect Dis 176 5 1997 1129 1134
3. A.G. Langenberg, R.L. Burke, S.F. Adair, R. Sekulovich, M. Tigges, and C.L. Dekker A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected] Ann Int Med 122 12 1995 889 898
4. C.M. Posavad, D.M. Koelle, M.F. Shaughnessy, and L. Corey Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses Proc Natl Acad Sci USA 94 19 1997 10289 10294
5. D.M. Koelle, C.M. Posavad, G.R. Barnum, M.L. Johnson, J.M. Frank, and L. Corey Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes J Clin Invest 101 7 1998 1500 1508
6. D.M. Koelle, H.B. Chen, M.A. Gavin, A. Wald, W.W. Kwok, and L. Corey CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells J Immunol 166 6 2001 4049 4058
7. A. Forrester, H. Farrell, G. Wilkinson, J. Kaye, N. Davis-Poynter, and T. Minson Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted J Virol 66 1 1992 341 348
8. E.A. Buckmaster, U. Gompels, and A. Minson Characterisation and physical mapping of an HSV-1 glycoprotein of approximately 115 × 10(3) molecular weight Virology 139 2 1984 408 413
9. U. Gompels, and A. Minson The properties and sequence of glycoprotein H of herpes simplex virus type 1 Virology 153 2 1986 230 247
10. P.J. Desai, P.A. Schaffer, and A.C. Minson Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes simplex virus type 1: evidence that gH is essential for virion infectivity J Gen Virol 69 Pt 6 1988 1147 1156
11. A. Wald, J. Zeh, S. Selke, T. Warren, A.J. Ryncarz, and R. Ashley Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons N Engl J Med 342 12 2000 844 850
12. A. Wald, L. Corey, R. Cone, A. Hobson, G. Davis, and J. Zeh Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment J Clin Invest 99 5 1997 1092 1097
13. M.E. Boursnell, C. Entwisle, D. Blakeley, C. Roberts, I.A. Duncan, and S.E. Chisholm A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease J Infect Dis 175 1 1997 16 25
14. S.L. Spruance, S.K. Tyring, M.H. Smith, and T.C. Meng Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study J Infect Dis 184 2 2001 196 200
15. T.W. Schacker, M. Conant, C. Thoming, T. Stanczak, Z. Wang, and M. Smith Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study Antimicrob Agents Chemother 46 10 2002 3243 3248
16. J.K. Hickling, S.E. Chisholm, I.A. Duncan, E.J. Taylor, C. Boswell, and C.S. McLean Abstracts of the 8th International Conference on Infectious Diseases Boston, MA Immunogenicity of a disabled infectious single cycle HSV-2 vaccine in Phase 1 clinical trials in HSV-2 seropositive and seronegative volunteers May 15-18, 1998
17. J.S.C. Roberts, J.A. Uttridge, J.K. Hickling, P.T. Loudon, C.S. McLean, and M.E. Boursnell Safety, tolerability, and viral containment of a disabled infectious single cycle HSV-2 vaccine evaluated in phase 1 clinical trials in HSV-2 seropositive and seronegative volunteers Abstracts of the 8th International Conference on Infectious Diseases Boston, MA May 15-18, 1998
18. D.S. Schmid, M.L. Thieme, H.E. Gary Jr., and W.C. Reeves Characterization of T cell responses to herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) using a TNF-beta ELISpot cytokine assay Arch Virol 142 8 1997 1659 1671
19. P.H. van der Meide, R.J. Groenestein, M.C. de Labie, J. Heeney, P. Pala, and M. Slaoui Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques J Med Primatol 24 4 1995 271 281